Tampa, FL 2 May, 2011 Leading drug database provider, Elsevier/Gold Standard, announced today that eHealthObjects, an innovative healthcare solutions company, which specializes in delivering healthcare technology products, solutions and platforms that can seamlessly be integrated with other systems, has chosen Alchemy as its drug database.
Alchemy is a complete drug database best known for its intelligent screening tools, which eliminate irrelevant and unnecessary alerts. Designed so that all clinical decision support logic can be performed in a single, instantaneous request, Alchemy works with any system configuration, ensuring quick and simple installation and adoption.
"The superior technical architecture of Alchemy made it an easy choice for us," said Sanjay Mittal, CEO for eHealthObjects. "Our mission is to provide our clients with the highest quality content in the most flexible format. Alchemy was the clear winner on both counts."
Alchemy will supply drug data to eHealthObject's ThinkHIE (Health Information Exchange Platform), ThinkEHR (Inpatient and Ambulatory Electronic Health Record) and ThinkCDM (Case and Disease Management) products. These products and solutions are recognized by industry experts for their interoperability and intuitive interfaces, which allow healthcare providers and clinicians to become comfortable with them in just a few hours, as opposed to weeks or months.
"We are delighted to provide drug data and decision support for the eHealthObjects solutions," said Trygve Anderson, Vice President of Product Management for Elsevier/Gold Standard. "Their dedication to developing solutions that configure to the specific needs of their clients aligns perfectly with the modern technical architecture of Alchemy, and we share a mutual goal of providing the best data to be used as needed without additional IT resources."
eHealthObjects has begun integrating Alchemy modules with its systems and expects to offer its customers ThinkHIE, ThinkEHR and ThinkCDM, including complete and automatically updating drug data, in May.
|Contact: Tom Reller|